GEN Exclusives

More »

GEN News Highlights

More »
Sep 4, 2008

Repligen Wins $1.125M in Grants to Enhance Preclinical Program in Friedreich's Ataxia

  • Repligen received $1.125 million in research grants to support the development of new treatments for Friedreich's ataxia. Funding will support preclinical activities until a compound is selected for clinical trials. Repligen will also use the money to develop biomarkers related to these drug candidates, which will be used to augment clinical development.

    Repligen obtained $1 million from the Muscular Dystrophy Association (MDA) and $125,000 from the Friedreich's Ataxia Research Foundation (FARA) and the National Ataxia Foundation (NAF).

    The MDA grant will partially support the characterization of the lead compounds, which have already been identified. This work includes the evaluation of compounds in preclinical models of disease and the completion of the pharmacology and toxicology.

    The FARA and NAF grant will support the development of new methods to quantitate the impact of drug treatment on frataxin gene expression and frataxin protein in preclinical models and in patients.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?